Filing Analysis
Officer Departure
Filed Apr 02, 2026
LOW
Cingulate Inc. appointed Zhanpeng “Frederick” Jiang to its Board of Directors as a Class I director, effective March 27, 2026. The appointment follows stockholder approval of an Issuance Proposal and is tied to a previously disclosed securities purchase agreement dated January 28, 2026.
Red Flags
- The director's appointment is subject to the terms of a 'securities purchase agreement' dated January 28, 2026, suggesting the seat may be a condition of a financing arrangement.
Key Facts
- Zhanpeng “Frederick” Jiang was appointed as a Class I director with a term expiring at the 2028 Annual Meeting of Stockholders.
- Mr. Jiang was appointed to the Audit, Compensation, and Nominating and Corporate Governance Committees.
- Compensation includes an annual cash retainer of $40,000 plus additional fees for committee service ($7,500 for Audit, $5,000 for Compensation, $4,000 for Nominating).
- Mr. Jiang was granted an option to purchase 15,000 shares of common stock, vesting in two equal installments over one year.
- The Board determined Mr. Jiang meets the independence requirements of Nasdaq Listing Rule 5605.
Securities Offering
Filed Mar 24, 2026
HIGH
Cingulate Inc. entered into a $100 million at-the-market (ATM) equity offering agreement and received shareholder approval for the issuance of shares related to a previous private placement of preferred stock and warrants.
Red Flags
- Significant potential dilution from a $100 million ATM facility relative to micro-cap valuation.
- Approval of common stock issuance for Series A Preferred Stock and warrants indicates further impending dilution.
- Multiple 8-K items (1.01 and 5.07) reported in a single filing.
Key Facts
- Entered into an ATM Sales Agreement with A.G.P./Alliance Global Partners on March 24, 2026.
- The ATM agreement allows for the sale of common stock for aggregate gross proceeds of up to $100,000,000.
- The company will pay a 3.0% commission to A.G.P. on gross proceeds from sales.
- Stockholders approved the issuance of common stock upon conversion of Series A Convertible Preferred Stock and warrants from a January 27, 2026 agreement.
- The stockholder approval was required to comply with Nasdaq Listing Rule 5635(b).
Regulation FD Disclosure
Filed Mar 18, 2026
LOW
Cingulate Inc. reported its full-year 2025 financial results and announced a significant intellectual property milestone for its lead ADHD candidate, CTx-1301.
Key Facts
- The company announced financial results for the fiscal year ended December 31, 2025, on March 18, 2026.
- The USPTO issued a Notice of Allowance on March 17, 2026, for a patent application covering lead asset CTx-1301 (dexmethylphenidate).
- The new patent protection for CTx-1301 is expected to extend through May 2042.
- CTx-1301 is being developed for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.